These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Johnson & Johnson (JNJ) reported better-than-expected third-quarter results, with adjusted earnings of $2.80 per share and sales of $23.99 billion, both surpassing analyst consensus. The company affirmed its fiscal year 2025 adjusted earnings guidance while raising its sales outlook. Additionally, J&J announced plans to separate its Orthopedics business to enhance strategic focus, though its shares saw a slight decline of 0.2% following the announcement.

Analysis

Johnson & Johnson (JNJ) reported robust third-quarter results, surpassing analyst expectations with adjusted earnings of $2.80 per share, a 15.7% year-over-year increase, and sales of $23.99 billion, up 6.8% year-over-year. The company further demonstrated confidence by raising its fiscal year 2025 sales guidance to $93.5 billion-$93.9 billion, exceeding the consensus of $93.44 billion, while affirming its adjusted earnings guidance of $10.80-$10.90. This indicates strong operational performance and a positive outlook for future revenue streams.

Concurrently, J&J announced strategic plans to separate its Orthopedics business, aiming to enhance strategic and operational focus across its remaining pharmaceutical and medtech segments. Despite the positive earnings beat and strategic restructuring announcement, JNJ shares experienced a slight decline of 0.2% to $190.48 following the news. This suggests the market may be digesting the implications of the spin-off or that the strong performance was largely anticipated.

Analyst sentiment remains broadly positive, with several firms raising their price targets for JNJ post-earnings. BofA Securities, Morgan Stanley, Raymond James, Stifel, and Citigroup all increased their targets, ranging from $190 to $215, with ratings predominantly Neutral to Buy/Outperform. This collective upward revision in price targets reflects underlying confidence in J&J's fundamentals and future value creation, despite the immediate market reaction.

Key Decisions for Investors

• Investors should monitor the execution and timeline of the Orthopedics business separation, as it could unlock value and sharpen the focus of JNJ's core segments.
• Consider the raised sales guidance and strong Q3 performance as indicators of fundamental strength, potentially supporting long-term valuation despite the immediate post-earnings share price dip.
• Evaluate the updated analyst price targets and ratings as a consensus view on JNJ's future prospects, particularly in light of the strategic restructuring and affirmed earnings outlook.